DNA-hsp65, a DNA vaccine encoding the 65-kDa heat-shock protein of Mycobacterium leprae (Hsp65) is capable of inducing the reduction of established tumors in mouse models. We conducted a phase I clinical trial of DNA-hsp65 in patients with advanced head and neck carcinoma. In this article, we report on the vaccine's potential to induce immune responses to Hsp65 and to its human homologue, Hsp60, in these patients. Twenty-one patients with unresectable squamous cell carcinoma of the head and neck received three doses of 150, 400 or 600 mg naked DNA-hsp65 plasmid by ultrasound-guided intratumoral injection. Vaccination did not increase levels of circulating anti-hsp65 IgG or IgM antibody, or lead to detectable Hsp65-specific cell proliferation or interferon-g (IFN-g) production by blood mononuclear cells. Frequency of antigen-induced IL-10-producing cells increased after vaccination in 4 of 13 patients analyzed. Five patients showed disease stability or regression following immunization; however, we were unable to detect significant differences between these patients and those with disease progression using these parameters. There was also no increase in antibody or IFN-g responses to human Hsp60 in these patients. Our results suggest that although DNA-hsp65 was able to induce some degree of immunostimulation with no evidence of pathological autoimmunity, we were unable to differentiate between patients with different clinical outcomes based on the parameters measured. Future studies should focus on characterizing more reliable correlations between immune response parameters and clinical outcome that may be used as predictors of vaccine success in immunosuppressed individuals.
Introduction
Heat-shock proteins (HSPs) are highly conserved maintenance proteins present in all cells of all living organisms, and are involved in the folding and transport of intracellular polypeptides. 1, 2 The 60-kDa family of heatshock proteins (Hsp60) are also immunodominant antigens in a number of bacterial infections, and are considered as potential targets for the development of vaccines against bacterial diseases. In addition, the proposed function of Hsp60 in activating the innate immune response 3 and the ability of HSPs in general to enhance antigen presentation, especially cross-presentation, 4 have led to investigations on the use of these proteins in cancer immunotherapy.
DNA-hsp65, a DNA vaccine encoding the Hsp60 homologue of Mycobacterium leprae (Hsp65), was initially developed as a prophylactic 5 and therapeutic 6 vaccine against tuberculosis. This same vaccine was later shown to elicit potent antitumoral responses in a mouse tumor model. 7 In this model, intraperitoneal injection of DNAhsp65 into mice with established peritoneal tumors led to reduction of tumor volume, an effect apparently related to the induction of an adaptive immune response to tumor antigens.
Our group has recently conducted a phase I clinical trial using DNA-hsp65 as a therapeutic vaccine in patients with advanced forms of head and neck squamous cell carcinoma. 8 In this study, the toxicity and side effects of different doses of DNA-hsp65 were evaluated in 21 patients; however, the immune response elicited by vaccination was not extensively characterized. Although data from the animal models suggest that specific immune response to Hsp65 does not seem to be critical for the vaccine's antitumoral effects in cancer, 7 the proposed use of DNA-hsp65 for the prevention and treatment of tuberculosis and the fact that this is the first time this vaccine is used in humans justify further analysis of its immunogenic potential.
A further concern in this trial was the potential HSPbased vaccines have to elicit pathological autoimmune responses due to the high level of sequence conservation between homologues from different species. This concern is based on observations that implicate self Hsp60 as a target antigen in different human autoimmune diseases, [9] [10] [11] and on evidence that such responses may be generated by postinfectious cross-reactivity between the highly conserved bacterial and human homologues. 12 Here, we provide a more extensive analysis of immune reactivity to Hsp65 in patients participating in the phase I trial, including measures of humoral and cellular responses to the antigen. In addition, we also evaluated whether vaccination with DNA-hsp65 was capable of inducing alterations in autoreactivity to Hsp60 in these patients. These data will be important both for the continuation of the use of DNA-hsp65 as an immunotherapeutic agent and for its proposed use in the prevention and treatment of tuberculosis.
Materials and methods

Study patients
The phase I trial included 21 patients recruited at the Clinical Hospital of the School of Medicine of the University of Sao Paulo. All patients had end-stage squamous cell carcinoma of the head and neck, with progressive disease after standard therapies. Inclusion and exclusion criteria are described elsewhere;
8 these included at least 3 months life expectancy, absence of lymphopenia and absence of radiotherapy, chemotherapy, or surgery for at least 1 month. Patient demographic and baseline clinical features, including all characteristics deemed relevant to the evaluation of immune status, are presented in Table 1 . The study protocol was approved by the hospital's institutional review board (CAPPesq 183/2) and by the Brazilian National Ethics Committee (CONEP). All patients signed terms of free and informed consent.
Immunization
The 21 patients were divided into three dose groups: Group A (150 mg; 6 patients), Group B (600 mg; 6 patients) and Group C (400 mg; 9 patients). Each patient received three doses of the indicated amount of DNA-hsp65, administered by ultrasonography-guided intratumoral injection at 3-week intervals, as previously described. 8 
Blood samples
Venous blood samples were collected in both heparinized and dry tubes. Peripheral blood mononuclear cells (PBMC) were separated from heparinized samples by centrifugation in a Ficoll-Hypaque gradient (density ¼ 1.077 g l À1 ) and cryopreserved in medium containing 90% fetal calf serum and 10% dimethyl sulfoxide for later analysis. Serum collected in dry tubes was left at room temperature to coagulate, and was later separated by centrifugation and stored at À80 1C. All time points from a same patient were assayed simultaneously.
Antigens
Recombinant M. leprae Hsp65 used in both cellular and humoral assays was a kind gift from Dr M Singh (Lionex, Germany). For cellular assays, contaminant endotoxin was removed in our laboratory using Triton X-114. 13 Final endotoxin content was o1 EU mg À1 of protein, as determined by Limulus amoebocyte lysate assay (BioWhittaker QCL-1000; Cambrex, Walkersville, MD). Recombinant human Hsp60 for humoral assays was produced in Escherichia coli bacteria in our laboratory and purified by nickel-histidine affinity chromatography, as described. 14 The recombinant human Hsp60 used for cellular assays was purchased from Lionex GmbH (Braunschweig, Germany).
Antibody ELISA Total IgG and IgM reactivity to Hsp65 and Hsp60 was determined by direct enzyme-linked immunosorbent assay (ELISA). High-binding 96-well plates (Costar, Cambridge, MA) were coated with 1 mg ml À1 Hsp65 or Hsp60 in carbonate-bicarbonate buffer (pH 9.6) then blocked with 0.25% gelatin (Sigma-Aldrich, St Louis, MO). Serum samples were added in duplicate at 1:100 dilution. Antibodies were detected using horseradish peroxidase (HRP)-conjugated mouse anti-human total IgG (BD Pharmingen, San Jose, CA) at 1:60 000 dilution or HRP-conjugated mouse anti-human IgM (BD Pharmingen) at 1:10 000 dilution. The reaction was developed using H 2 O 2 /o-phenylenediamine (Sigma-Aldrich) as a substrate. Absorbance (abs.) was read at 492 nm and the mean abs. of wells without sample (blank) was subtracted from the reactivity of samples in the same plate.
Proliferation assays
Proliferation assays were carried out as previously described. 15 Briefly, 2 Â 10 5 PBMC per well were cultured in U-bottom 96-well plates in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% inactivated pooled human serum. Cells were incubated in quadruplicate, either unstimulated or stimulated with 10 mg ml À1 Hsp65 or Hsp60 or 5 mg ml
À1
phytohemagglutinin-P (PHA-P) as a positive control (Sigma-Aldrich). Cultures were maintained at 37 1C in 5% CO 2 for 5 days, after which 0.5 mCi per well thymidine-3 H (Amersham, Buckinghamshire, UK) was added for 18 h. 
Enzyme-linked immunospot assay
Enzyme-linked immunospot (ELISpot) assays were performed using BD interferon-g (IFN-g) and interleukin-10 (IL-10) Human ELISpot Sets (Benton Dickinson, San Jose, CA), according to the manufacturer's instructions. Briefly, 10 5 PBMC suspended in RPMI media (Gibco BRL, Grand Island, NY) with 10% fetal calf serum (Gibco BRL) were cultured in duplicate for 44 h at 37 1C and 5% CO 2 on anti-IFN-g or anti-IL-10-coated 96-well plates. Cells were either left unstimulated or stimulated with 10 mg ml À1 Hsp65 or Hsp60 or 5 mg ml À1 PHA-P as a positive control. Cytokine production was detected using biotinylated secondary anti-IFN-g or anti-IL-10 antibodies followed by incubation with streptavidin-HRP and AEC substrate (BD Pharmingen). Spots were counted using an automated ELISpot reader with KS Elispot software (Zeiss, Germany) or manually when the density of spots was too high for accurate automated counting (typically X500 spots per well). Results are expressed as net spot-forming units (SFU) per 10 6 cells (mean number of SFU in duplicate stimulated wellsÀSFU in unstimulated wells Â 10). IFN-g production was considered as positive when net production was X50 SFU per 10 6 cells and at least twice the unstimulated production.
Clinical follow-up
Response to treatment was considered in terms of variation in tumor volume according to the Response Evaluation Criteria in Solid Tumors (RECIST):
16 no evidence of disease was considered as a complete response; partial response applies to a greater than 30% decrease in tumor volume; stable disease corresponds to less than 30% decrease and less than 20% increase in tumor volume and progression corresponds to greater than 20% increase in tumor volume. Delayed type hypersensitivity was assayed as described in the clinical trial paper. 8 
Statistical analysis
Percent variation from baseline for all parameters was calculated as (HPÀpre)/pre Â 100, where HP is the highest postvaccination measurement available and pre is the prevaccination measurement. The statistical significance of differences between progressors and nonprogressors was calculated using the Mann-Whitney U-test. Statistical analyses were performed using GraphPad Prism for Windows version 4.0.
Results
Sample collection
We collected venous blood samples from patients before each dose of vaccine (days 1, 21 and 42), 1 week after the last dose (day 49) and, when possible, at 3, 6 and 12 months after the initial dose. Owing to the poor health of most patients, not all samples could be collected and/or analyzed. Reasons for sample loss were most often related to clinical counterindication for blood withdrawal or insufficient number and/or viability of cells after separation or thawing. Of the 93 possible samples from 21 patients, we were able to assay 62 samples from 16 patients for antibody production, 45 samples of 11 patients for lymphoproliferation and 50 samples from 13 patients for cytokine production.
Response to Hsp65 Figure 1 shows patient antibody responses to Hsp65 before and after vaccination. Baseline (prevaccination) total IgG reactivity to Hsp65 varied widely between patients ( Figure 1a) ; however, there was no substantial increase (X2-fold) in reactivity in any of the patients studied, irrespective of dose group. A single patient showed a more pronounced change in reactivity (patient no. 21, indicated by an asterisk), with a 60% increase from abs. ¼ 0.42 at baseline to 0.67 on day 42. There was also no substantial increase in IgM reactivity to Hsp65 after immunization (Figure 1b) .
Patient PBMC responses upon ex vivo stimulation with Hsp65 are presented in Figure 2 . We were unable to detect IFN-g production upon stimulation with Hsp65, either before or after vaccination, regardless of vaccine dose (Figure 2a ). All cell samples produced high levels of IFN-g in response to PHA. Proliferation in response to Hsp65 was essentially negative ( Figure 2b) ; with only one patient in the highest dose group (no. 11, Group B) showing borderline proliferation (SI ¼ 2.06) 1 week after the third dose of vaccine. This patient showed stable disease, with a 2% reduction in tumor volume between the two evaluations, and eventually died of disease progression 228 days after the beginning of treatment ( ).
One patient (no. 21, Group C) responsive to Hsp65 before vaccination (SIB2.5) became negative after the first dose of Hsp65 and remained so throughout the evaluation. This patient showed progressive disease and died after 127 days (Table 2) . Unlike IFN-g, IL-10 was produced in response to Hsp65 by a high proportion (up to 1%) of the PBMC of most patients (Figure 2c ). IL-10 production varied greatly during treatment, with some patients (4 of 13) showing at least twofold increases after vaccination (for example, patient no. 21, Group C, from 1585 SFU per 10 6 PBMC at the baseline to 9285 SFU per 10 6 PBMC on day 49). All patients with obvious alterations (X2-fold) in the number of cells producing IL-10 in response to Hsp65 (4 increases and 1 decrease) also showed similar alterations in other unrelated measures, such as IL-10 production in response to tetanus toxoid, spontaneous lymphoproliferation and production of IFN-g, both unstimulated and in response to PHA (data not shown). These data suggest that the modulation in IL-10 production was not specific to Hsp65, but could reflect a more general modulation in the global activation state of the patients, as described in the clinical trial paper. 8 As discussed below, production of IL-10 appears to be unrelated to clinical progress.
Response to Hsp65 according to clinical evolution In Table 2 we present a summary of overall patient responses to Hsp65, as well as selected clinical information on each patient. Based on the RECIST criteria, 16 of 21 patients enrolled, 4 showed partial regression in tumor Immune response to DNA-hsp65 vaccination GD Victora et al Immune response to DNA-hsp65 vaccinationvolume (nos. 1, 3, 4 and 10), 1 showed stable disease (no. 11), 9 showed disease progression and 7 could not be evaluated or died before the second measurement at day 49. In Figure 3 we compare patients classified as nonprogressors (partial regression or stable disease) with those classified as progressors (disease progression or death before second analysis) in terms of percent change from baseline immune responses to Hsp65. As shown in the figure, both groups showed similar variation in all four parameters compared (serum antigen-specific IgG and IgM and PBMC proliferation and IL-10 production upon stimulation with antigen). Because IFN-g production was never above background in any of the patients or time points analyzed, these data were not included in the comparison. None of the comparisons approached statistical significance; however, nonsignificant P-values must be interpreted with caution due to the small number of subjects and the resulting lack of statistical power.
Individual responses
The individual results of three patients we consider the most relevant to the study are presented in Figure 4 . The first patient shown is no. 1 (Group A), who received an additional three doses of 150 mg of DNA-hsp65 as compassionate treatment between days 180 and 240, totaling six doses of vaccine. This patient showed a substantial reduction in tumor volume (450%) and survived for more than 1 year after the first dose of vaccine. As seen in the figure, no increase in IgG levels and no IFN-g or proliferative responses were detectable in this patient even after six doses of DNA-hsp65. This patient showed a decrease in number of cells producing IL-10 in response to Hsp65 during the first three-dose protocol, and an increase in this number during compassionate treatment. The second patient, no. 10 (Group B), showed reduction and stabilization of tumor size after treatment, and is alive more than 3 years after the beginning of treatment. This patient apparently showed no systemic reaction to the vaccine, with low antibody, and no IFN-g, and proliferative responses to Hsp65. Although the frequency of IL-10-producing PBMC more than doubled between baseline and day 49, levels at day 49 (255 SFU per 10 6 PBMC) were still very low when compared to those of the majority of patients (Figure 2c ). This patient was purified protein derivative (PPD) negative at baseline, but responded positively (10 mm in duration) after vaccination (Table 2) ; however, this was not accompanied by a positive IFN-g ELISpot. The third patient, no. 21, had an intense clinically diagnosed local inflammatory response to the vaccine, including pain, edema and lymph-node engorgement, 8 and showed the greatest increase in both antibody levels and IL-10 production to Hsp65. This patient also showed a concomitant decrease in lymphoproliferation-which may indicate the negative influence of the intense IL-10 production-and negative PPD following vaccination. Despite displaying some increase in antibody to Hsp65 and signs of local tumor inflammation, this patient showed the greatest relative increase in tumor volume (4500%), and died after 127 days (Table 2 ).
Response to Hsp60
We found no obvious alteration (X2-fold) in total IgG reactivity to Hsp60, regardless of dose group (Figure 5a) . The results of IFN-g production and lymphoproliferation were less homogeneous. Of 13 patients tested, 8 showed detectable numbers of cells producing IFN-g when stimulated with human Hsp60 in at least one of the time points analyzed (Figure 5b ). Of these, five had detectable IFN production already at the baseline and two lacked the baseline sample for comparison. A single initially unresponsive patient showed a positive response following vaccine administration (patient no. 11, Group B, at day 21), but this response was of small magnitude (55 SFU per 10 6 PBMC), and fell below the detection threshold again at days 42, 49 and 90. In the proliferation Figure 3 Response to Hsp65 according to clinical outcome. Patients are divided into nonprogressors (decreased or stable tumor volume, empty squares) or progressors (increased tumor volume or death before second evaluation, filled squares). Only patients with prevaccination and at least one short-term postvaccination sample (days 21, 42 or 49) are included. When more than one postvaccination sample was available, that with the highest value is represented. Data are presented as percent change between pre-and postvaccination samples. One progressor was excluded from IgM analyses due to very low pre-and postvaccination levels (abs.40.03). Assays were performed as in Figures 1 and 2 . P-values are for Mann-Whitney U-test. assays, 4 of 11 patients analyzed showed SI X2 in at least one time point (Figure 5c ). Of these, three had positive results already at the baseline, and only one patient initially negative (no. 8, Group B) became borderline positive (SI ¼ 2.21) after one dose of vaccine; this was not the same patient who showed positive proliferation to mycobacterial Hsp65 after vaccination (no. 11, Group B).
Discussion
In this study, we evaluate HSP-specific immune responses in patients with advanced stages of head and neck carcinoma after vaccination with DNA-hsp65. According to the parameters measured, these patients showed essentially no antibody or proinflammatory cellular responses to the vaccine antigen, regardless of vaccine dose (Table 2 ). This is in overt contrast to the results obtained in animal models of the vaccine, which showed intense IFN-g and IgG responses after vaccination. 5, 6 In addition to the differences in experimental system and to the generally immunosuppressed state of advanced cancer patients, our contrasting results may also reflect the greater difficulty in achieving robust immune responses with DNA vaccination in large animals when compared to rodents. [17] [18] [19] We chose to evaluate three established markers of immune activation and vaccine effectiveness, namely serum IgG levels, IFN-g production and lymphocyte proliferation. We also evaluated IL-10 production, given the evidence that this cytokine may be produced in response to Hsp65, 20 and may negatively affect immunization. Of special interest to us given the vaccine's intended use as prophylaxis against tuberculosis was the production of IFN-g in ELISpot assays, because this is the most accepted correlate of protection against M. tuberculosis infection. 21 We were unable to detect IFN-g production upon stimulation with Hsp65 in any of the patients before or after vaccination. This was true even in patients with positive skin reactions to PPD, which contains Hsp65 (Table 1; see also clinical trial  paper   8 ). Likewise, the two patients initially unresponsive to PPD but who became responsive after vaccination (patients no. 4 and 10, Table 2 ) remained negative for Hsp65 IFN-g ELISpot. Nevertheless, both of these patients showed a more favorable outcome with reductions in tumor size and extended survival (both are still alive more than 3 years after treatment). Such discrepancies may be due to the greater specificity of the Hsp65 ELISpot assay when compared to the PPD skin test. 21, 22 On the other hand, these data suggest that conversion to positive PPD may be a better readout for an effective antitumor response in this system.
Five patients showed disease regression or stability following treatment according to RECIST criteria. 16 Of these, four (three disease regression, one stable disease) had enough material collected to be analyzed in terms of response to Hsp65. A comparison of these patients with those showing progressive disease failed to reveal any statistically significant differences. A possible explanation for this is that the parameters analyzed-in spite of being common surrogate measures of vaccine efficacy-may not be appropriate markers for the immune responses necessary to induce tumor rejection. An example of this is patient no. 10, who, in spite of showing extensive tumor regression and surviving for over 3 years after completion of immunotherapy, was virtually indifferent to vaccination according to the parameters measured ex vivo. Another potential explanation is related to the assumption underlying our approach-namely that immunization against tumor antigens is correlated to immunization against the 'carrier' Hsp65, which is measured in the assays. It is conceivable that immunization against tumor antigens may have occurred in responding patients in the absence of immunization against Hsp65, and therefore remained undetected by our assays. In addition, taken that HSP-peptide complexes may induce both innate and adaptive immune responses to the tumor, the evaluation of parameters of innate immunity may provide relevant correlates of vaccine efficacy. 23 Another caveat in interpreting our results is the immunosuppression that is characteristic of patients with advanced stages of head and neck cancer. 24 Although this may be a general characteristic of such patients, at least some of the subjects included in this study showed evidence of immune activity, including positive response to skin tests (7 of 21 patients) and high unstimulated lymphoproliferation (41000 c.p.m.; 8 of 11 patients) ( Table 2 and clinical trial paper   8 ). The observation that of the five nonprogressors, four were either positive for skin tests or showed spontaneous lymphoproliferation 41000 c.p.m. at some point during the course of treatment (proliferation was not measured for the other patient, no. 3) suggests that measurable immune activity may be required for a favorable response to treatment. Also, only 1 patient (no. 16) was lymphopenic at the baseline (Table 2 ). This patient showed disease progression, and died at day 181 after treatment.
A feature that distinguishes the current approach from previous tumor immunotherapy strategies is the use of the intratumoral route for immunization. This is based on the assumption that Hsp65 will serve as a chaperone to tumor-specific antigens, effectively presenting these antigens to the adaptive immune system. 7 However, the use of the intratumoral route is complicated by the highly immunosuppressive microenvironment of the head and neck tumor. 24 Further studies must be conducted to determine whether presentation of tumor antigens by Hsp65 is required for its antitumoral effects or whether these effects are mediated by a reversion of immunosuppression mediated by the proinflammatory properties of this protein. If the latter is true, immunization away from the tumor (for example, skin at a distant site) may prove more efficient in achieving tumor regression by averting the effects of local immunosuppression.
We found a high frequency of cells producing IL-10 in response to Hsp65 in most patients, both before and after vaccination. IL-10 production increased at least twofold in 4 of 13 patients in the course of treatment, suggesting that the vaccine may have biased these patients toward a dominant IL-10 immune response. This has been shown to occur in mouse models of cancer, 25 and may explain the lack of detectable lymphoproliferation and IFN-g production to Hsp65 in this study. This seems to indicate that host conditions are of particular importance with respect to the effects of mycobacterial Hsp65 on the immune response. In support of this notion are the observations in mice that vaccination with the same DNA-hsp65 construct can induce both strong Th1 immune responses, 5, 6, 26, 27 and regulatory responses marked by production of IL-10, 28, 29 depending on the experimental model employed. Once again, the intratumoral route of immunization used in this study may have contributed toward this effect.
There were no modifications in either cellular or humoral reactivity to human Hsp60 that could suggest increased disposition to the development of autoimmune reactions. Although overall reactivity to Hsp60 was higher than reactivity to Hsp65 (Figures 1, 2 and 5) , neither antibody production, lymphocyte proliferation nor IFN-g production were found to consistently increase after vaccination ( Figure 5 ). These results were expected for two reasons. First, the lack of a strong Th1 response to Hsp65 in these patients suggests that they were unable to mount a proinflammatory immune response to the vaccine antigen; therefore, the development of autoreactivity and/or pathogenic autoimmunity due to crossrecognition of Hsp65 and Hsp60 was unlikely. Second, although in animal models, injection of mycobacterial products can induce proinflammatory autoimmune clones that recognize Hsp65, 30, 31 immunization with purified protein or even with DNA-hsp65 itself, seems almost invariably to induce protection against autoimmune disease, 29, 30, 32 with the possible exception of two highly susceptible animal models. 33, 34 Taken together, our results show that, although our measurements were able to detect some degree of immunostimulation by DNA-hsp65, we were unable to differentiate between patients with different clinical outcomes based on the parameters measured. This suggests that current markers of vaccine efficacy, including those used in tumor immunotherapy, may not be adequate in immunosuppressive contexts, such as in cancer and HIV infection. Along these same lines, the recent failure of the Merck HIV-1 vaccine in humans has motivated the search for a more thorough evaluation of vaccine-induced immune responses to better correlate with clinical efficacy. 35, 36 Because DNA-hsp65 was deemed safe for use in phase II clinical trials, 8 it will be important to determine, in healthier individuals, and using a broader spectrum of assays, what type of immune responses are induced by this vaccine in patients who respond favorably to treatment. This information will be essential to the establishment of more reliable correlates of vaccine efficacy that can be used as predictors of vaccine success.
